HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful treatment of type B insulin resistance with rituximab.

AbstractCONTEXT:
Type B insulin resistance is a very rare disease caused by autoantibodies against the insulin receptor. The mortality of type B insulin resistance is high (>50%), and management of this disease is not yet standardized. We report the successful treatment of a patient with type B insulin resistance with rituximab, cyclophosphamide, and prednisone.
CASE DESCRIPTION:
A 45-year-old woman presented with unintended weight loss of 20 kg, unusually widespread acanthosis nigricans, and glucose levels > 500 mg/dL, which could not be controlled with up to 600 IU/d of insulin. Because of the severity of the insulin resistance combined with features of insulin deficiency, type B insulin resistance was suspected. Detection of high levels of insulin receptor autoantibodies confirmed the diagnosis. Neither immunosuppressive therapy with Ig iv nor plasmapheresis had an effect on glucose levels or insulin dose. Because the patient's condition was deteriorating, we started rituximab (750 mg/m(2) in two doses 2 wk apart) together with cyclophosphamide (100 mg/d orally) and dexamethasone 40 mg/d for 4 days. Two months after initiation of rituximab therapy, fasting glucose levels ranged from 80 to 110 mg/dL and could be controlled with very low insulin doses. Glycated hemoglobin decreased from 11.8 to 6.5%. Two months later, insulin therapy was stopped, and the patient showed normal blood glucose readings.
CONCLUSION:
In this patient with type B insulin resistance, Ig treatment and plasmapheresis failed to improve the condition. Finally, treatment with rituximab, cyclophosphamide, and steroids was successful in inducing a complete remission.
AuthorsEmmanouil-Dimitrios Manikas, Iona Isaac, Robert K Semple, Rana Malek, Dagmar Führer, Lars C Moeller
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 100 Issue 5 Pg. 1719-22 (May 2015) ISSN: 1945-7197 [Electronic] United States
PMID25675382 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Autoantibodies
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Rituximab
  • Receptor, Insulin
Topics
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Autoantibodies (immunology)
  • Autoimmune Diseases (drug therapy, immunology, therapy)
  • Female
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Immunologic Factors (therapeutic use)
  • Insulin Resistance (immunology)
  • Middle Aged
  • Plasmapheresis
  • Receptor, Insulin (immunology)
  • Retreatment
  • Rituximab
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: